New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Natural health product Libidfit may pose health risks

OTTAWA, Jan. 26 /CNW Telbec/ - Health Canada is warning consumers not to
use the natural health product Libidfit because it has been found to contain
an undeclared ingredient that could lead to serious health risks, especially
for patients with existing medical conditions such as heart problems.

Libidfit is promoted for sexual enhancement and erectile dysfunction, but
contains an undeclared amount of a pharmaceutical ingredient similar to
sildenafil, which could pose a health risk when used without medical
supervision, especially in those individuals who may be taking heart
medications or who have heart problems or are at risk for strokes. Sildenafil
has also been associated with serious side-effects including sudden vision
loss, penile tissue damage and urinary tract infection.

This product is not authorized for sale in Canada, but it may be
available to Canadian consumers through personal importation, the Internet or
other venues. Canadians who may have purchased Libidfit over the Internet or
while travelling abroad are warned not to use it, and to consult with a health
care professional if they have concerns about their health due to this

Libidfit is manufactured by Libidfit AG, and has been found for sale in
Denmark and on the Internet. As a result, the Danish Medicines Agency issued a
public warning about the risks associated with Libidfit.

Health Canada also advises Canadians to contact the Health Products and
Food Branch Inspectorate at 1-800-267-9675 if they find Libidfit products in
Canada. Health Canada has notified the Canada Border Services Agency to detain
any shipment of Libidfit at the border.

To date, no adverse reactions from the use of this product has been
reported in Canada. To report a suspected adverse reaction, please contact the
Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada by
one of the following methods:
Telephone: 866-234-2345
Facsimile: 866-678-6789

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.